Novo Nordisk A/S Price Today
Novo Nordisk A/S
NVO
Healthcare
$417.93B
💰
Market Cap
44.5
💸
Price to Earnings
$2.1
🎉
EPS
+0
🌳
ESG
Consensus Recommendations
Strong_buy Consensus
Buy |
12 |
Strong Buy |
5 |
Hold |
10 |
Sell |
2 |
Strong Sell |
2 |
NVO Price Forecast Target
93.5 👉 105.5 +13%
NVO EPS Forecast
2.1 👉 2.6 +25%
Financials
Profit Margin
33 %
Revenue Growth
31.6 %
Dividend
$ 1.03
Held Percent
0.0% - Insiders
8.2% - Institutions
91.8% - Public
Major Fund Holders
-
💰 Jennison Associates LLC $1.9B
-
💰 Renaissance Technologies, LLC $1.5B
-
💰 Fisher Asset Management, LLC $1.2B
-
💰 Bank of America Corporation $1.0B
-
💰 FMR, LLC $877.6M
Stock Ideas
Nelson Peltz Portfolio
Nelson Peltz is a renowned investor known for his astute investment strategies and activist approach. With a portfolio spanning diverse industries, Peltz strategically targets underperforming companies, advocating for changes that unlock their full …
Seth Klarman Portfolio
Seth Klarman's investment prowess is exemplified by his exceptional track record. Since the inception of his fund until 2008, he achieved an impressive compound return-on-investment of 20%. This remarkable achievement showcases his astute investment…
Ken Fisher Portfolio
Ken Fisher is a prominent American investment analyst, author, and the founder of Fisher Investments, a global investment firm managing billions of dollars in assets for individual and institutional clients. As a highly successful investor and fina…
Bill Ackman Portfolio
Bill Ackman, a renowned investor, has established himself as a long-term value investor with a keen eye for short-term price fluctuations. His expertise lies in special situations investments, and his Pershing Square portfolio reflects a highly conc…📮FAQ
Some Frequently Asked Questions.
The Novo Nordisk A/S industry is Biotechnology
The Novo Nordisk A/S sector is Healthcare
The Novo Nordisk A/S forecasted predicted Price to Earnings PE ratio is 35.6
The Novo Nordisk A/S Price to Earnings PE ratio is 44.5
The Market Capitalization of Novo Nordisk A/S is $417.93B
There are total of 3214407936 float shares with 8.2% held by Institutions and 0.0% held by insiders
The MNovo Nordisk A/S forecasted Earnings per Share EPS is $2.6
The Novo Nordisk A/S Earnings per Share EPS is 2.1
The Novo Nordisk A/S company has $148506000000 gross profits with 33 profit margins
The Novo Nordisk A/S Earnings Growth is 0.473% with 0.459% quarterly earnings growth
The Novo Nordisk A/S Revenue is $201325002752 with 0.316 revenue growth
The price target for Novo Nordisk A/S stock is $105.5 for the high target and $58.2 for the low target
The consensus analyst recommendations for Novo Nordisk A/S is Strong_buy, however the decision to buy or sell the stock should be entirely yours, as you are earning your own money and hence responsible on how to allocate and spend them.
The consensus analyst recommendations for Novo Nordisk A/S is Strong_buy, with the following breakdown:
- Buy: 12
- Strong Buy: 5
- Hold: 10
- Sell: 2
- Strong Sell: 2
The Beta of Novo Nordisk A/S is 0.2
The dividend of Novo Nordisk A/S is $1.03
The dividend yield of Novo Nordisk A/S is 0.011%
The biggest institutional and mutual fund holders of Novo Nordisk A/S stock are
- Jennison Associates LLC
- Renaissance Technologies, LLC
- Fisher Asset Management, LLC
- Bank of America Corporation
The Novo Nordisk A/S ESG Score is 0, with the following breakdown:
- E: 0
- S: 0
- G: 0